Introduction
============

Globally, tuberculosis (TB) presents as the most common opportunistic infection in people with HIV.[@b1-idr-11-1413] In the latest global TB report, the World Health Organization estimated that 10% of the 10.4 million incident cases of TB in 2016 were coinfected with HIV. Sub-Saharan Africa bears the highest rates of HIV-associated TB, with coinfection rates of up to 50% in some areas.[@b1-idr-11-1413] In HIV-uninfected individuals with latent TB infection, the lifetime risk of TB reactivation disease is 10%. This risk is increased to 10% per annum in HIV-infected patients.[@b2-idr-11-1413] In addition to the increased risk of TB reactivation, HIV coinfection has also been reported as a significant risk factor for recurrent TB disease. Weakened immune responses, a hallmark characteristic of HIV infection, facilitates the progression to active TB disease and is a significant risk factor for recurrent TB disease.[@b3-idr-11-1413] HIV--TB coinfection is further complicated by the development of drug resistance in *Mycobacterium tuberculosis*.[@b4-idr-11-1413]--[@b6-idr-11-1413]

Recurrent TB disease, following cure or successful treatment completion, occurs as a result of either relapse (recurrence of the previous infection) or reinfection (infection with a new strain type), each associated with its own risk factors. Risk factors associated with individual vulnerability including immune compromise due to comorbidities such as HIV coinfection and diabetes mellitus, residual lung damage due to previous TB infection, age, malnutrition, and social risk factors such as alcohol abuse and cigarette smoking have been attributed to both relapse and reinfection. Risk factors that impact on treatment response such as inadequate treatment regimen, poor treatment adherence, and unrecognized drug resistance or host-specific factors that affect drug metabolism have been attributed to relapse of TB disease. Increased risk due to poor epidemic or infection control resulting in repeat exposure has been attributed to reinfection. Distinguishing between relapse and reinfection requires comparing the homology of *M. tuberculosis* strains isolated during the first and recurrent TB episodes using molecular-based DNA fingerprinting techniques.[@b7-idr-11-1413],[@b8-idr-11-1413]

Complex multi-drug regimens and optimal medication adherence are required for effective treatment of TB/HIV coinfection.[@b9-idr-11-1413]--[@b11-idr-11-1413] This results in challenges of adherence to complex dosing strategies, long duration of therapy, serious and often life-threatening drug side effects, and drug--drug interactions.[@b11-idr-11-1413] Adherence, a major factor undermining treatment outcomes, relies on patients' attitude, knowledge, and beliefs, which are in turn influenced by poverty, gender, stigma, and other social and cultural factors.[@b9-idr-11-1413]--[@b14-idr-11-1413] Patients failing TB treatment are likely to remain infectious thereby increasing the likelihood of ongoing transmission of infection.[@b9-idr-11-1413],[@b15-idr-11-1413],[@b16-idr-11-1413] We report and analyze five patients with HIV--TB coinfection, receiving concomitant treatment for both diseases and who subsequently developed recurrent drug-resistant TB (DR-TB). This report highlights the various risk factors that contributed to the development of recurrent TB.

Patients and methods
====================

We conducted a retrospective chart review on a subset of patients enrolled in the CAPRISA TRuTH study investigating the incidence of TB recurrence in adult TB/HIV-coinfected patients, who previously completed treatment for drug-sensitive pulmonary TB in the CAPRISA SAPiT trial.[@b17-idr-11-1413] The study was conducted between June 2005 and August 2013. Patients were followed up quarterly for 5 years. Among 82 patients who developed recurrent TB, five patients were diagnosed with recurrent DR-TB. Case notes were used to report the contributing risk factors to the development of recurrent TB.

Patients diagnosed were treated with standard TB treatment, and treatment outcomes were recorded as per the South African National TB control program guidelines.[@b18-idr-11-1413] Patients were initiated on a once-daily first-line antiretroviral treatment (ART) regimen and managed as per national guidelines.[@b19-idr-11-1413] Participants received TB treatment adherence -- counseling occurred prior to TB treatment initiation, and adherence was enhanced and verified through TB directly observed therapy short-course (DOTS) program. ART adherence support occurred through group counseling, two sessions prior to initiation, one on the day of treatment, and continued six-monthly thereafter. Adherence was assessed by clinic-based pill count at all scheduled visits, and six-monthly virologic outcomes. Adherence was described according to previously published categories by medication possession ratios and patient self-reporting.

To determine the mechanism mediating TB recurrence, initial and recurrent isolates were genotyped using the IS*6110* restriction fragment length polymorphism method.[@b22-idr-11-1413],[@b23-idr-11-1413] To assess the impact of HIV on TB recurrence, HIV virologic markers were assessed and stored plasma samples were analyzed for drug resistance conferring mutations prior to ART initiation, at the entry of the TRuTH study, and at the end of the study. HIV drug resistance sequencing incorporated the viral protease (codons 1--99) and reverse transcriptase (codons 1--230) genes. Drug resistance mutations were interpreted using the Stanford University HIV drug resistance database[@b16-idr-11-1413],[@b18-idr-11-1413] and the International AIDS Society mutation list.[@b19-idr-11-1413]

Ethical approval for the TRuTH study was obtained from the University of KwaZulu-Natal Biomedical Ethics Research Committee, reference number BF051/09; Clinical trials number NCT01539005. Written informed consent was obtained from all participants to publish case details and images with no personal identifiers.

Results
=======

In-depth clinical profiles for each patient are described in [Table 1](#t1-idr-11-1413){ref-type="table"}. The mean age was 34.8 (range, 30--38) years during the first TB episode. Among the five participants, two were female and three were male. One patient displayed a body mass index (BMI) of 17.0, falling within the underweight range during the recurrent TB episode. The remaining patients recorded BMI values in the normal range.

TB history and associated risk factors for recurrent TB
=======================================================

All five patients had a previous history of TB disease for which they received between 6 and 10 months of DS anti-TB treatment, before enrolling into the TRuTH study. Patients 1 and 5 subsequently developed XDR-TB, and the remaining patients developed MDR-TB. Patients 1, 2, and 3 presented with DR-TB in the TRuTH study 24, 28, and 19 months, respectively, after successful treatment completion for two prior episodes of DS-TB. Patients 4 and 5 presented with DR-TB during the TRuTH study 28 and 15 months, respectively, after successful treatment completion for one episode of DS-TB. Assessment of radiographic chest X-rays during initial TB infection, point of cure for initial TB episode, and TB relapse ([Figures S1](#SD1-idr-11-1413){ref-type="supplementary-material"}[](#SD2-idr-11-1413){ref-type="supplementary-material"}[](#SD3-idr-11-1413){ref-type="supplementary-material"}--[S4](#SD4-idr-11-1413){ref-type="supplementary-material"} and [Table 1](#t1-idr-11-1413){ref-type="table"}) indicated that recurrent TB infection was characterized by the presence of vast damage to the lungs and residual damage from prior TB infection. Month 2 sputum culture results were only available for patients 1 and 2, both of which remained positive. The remaining patients had only sputum smear results available, all of which were negative. Among the paired *M. tuberculosis* isolates representing the initial and recurrent TB episodes, there were two cases of TB reinfection (patients 1 and 3) and three cases of TB relapse (patients 2, 4, and 5). Detailed data on genetic profiles, drug susceptibility profiles, and timelines for recurrent disease episodes are reported in [Table 1](#t1-idr-11-1413){ref-type="table"}.

HIV coinfection and its impact on recurrent TB disease
======================================================

All five patients were diagnosed with HIV at screening of the SAPiT trial and initiated on standard treatment at various points during concomitant anti-TB therapy. The mean CD4^+^ T cell count was 171 cells/mm^3^ at diagnosis of the initial TB episode, 341,2 cells/mm^3^ at cure of the first TB episode and 289 cells/mm^3^ at diagnosis of recurrent TB. CD4 and viral load data for each patient are detailed in [Table 1](#t1-idr-11-1413){ref-type="table"}. Retrospective analysis of HIV drug resistance mutations demonstrated that the patients had no pre-ART drug resistance mutations. However, over the course of treatment and subsequent regimen changes, by the end of the study all patients developed dual class resistance with non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations featuring prominently. Protease inhibitor resistance mutations were not detected in any of the patients described. Detailed data on all resistance-associated mutations over the course of treatment are shown in [Table 2](#t2-idr-11-1413){ref-type="table"}.

Adherence and social risk factors
---------------------------------

There were various social risk factors and treatment adherence issues that played a role in the complex clinical course of these patients. Patient 1 had a history of alcohol abuse resulting in poor adherence, missed clinic visits, and discontinuation of ART for a period of 6 months. The patient's hospital admission also coincided with diagnosis of his recurrent TB episode. Patient 2 also had a reported history of alcohol abuse resulting in poor adherence and incarceration that coincided with his MDR-TB diagnosis. Patient 3 reported that her partner was HIV positive who was not on ART and declined condom use with her. In addition, this patient reported a low level of educational attainment. Patient 4 displayed poor adherence despite receiving intensive counseling under study conditions. She also reported close contacts with TB patients, no condom use, and low level of educational attainment. Patient 5 reported no significant adherence or social risk factors.

Discussion
==========

This series highlights the impact of various risk factors in the development of recurrent TB infection in five HIV-coinfected patients. We further highlight the considerable complexity in the management of coinfected patients because of the use of multiple drugs with complex dosing schedules, and prolonged treatment course that is often complicated by severe overlapping drug toxicities. Published data from various settings consistently demonstrate the impact of these factors on patient adherence and retention in care.[@b20-idr-11-1413],[@b21-idr-11-1413],[@b24-idr-11-1413],[@b25-idr-11-1413]

Notwithstanding the small sample size in this case series, the following important findings should be noted. All five patients were HIV coinfected with a previous history of TB infection and prior exposure to anti-TB treatment, residual lung damage, and demonstration of poor treatment adherence; significant risk factors linked to the development of recurrent TB disease. Furthermore, three of the five patients had multiple episodes of DS-TB infection with subsequent DR-TB infection. Strain typing revealed that recurrence occurred by relapse in three cases and by reinfection in two cases. While published reports attribute reinfection as the main mechanism of recurrence in the context of HIV coinfection, we demonstrated three cases of relapse in our study among HIV/TB-coinfected patients.[@b26-idr-11-1413]--[@b29-idr-11-1413] Furthermore, our data support findings of a recent South African study showing ongoing transmission of DR-TB, and the low rates of TB culture conversion including frequent reversion.[@b6-idr-11-1413]

We retrospectively analyzed the development of ART resistance mutations in our recurrent TB patients. Despite having no mutations at ART initiation, by the end of the study all five patients developed dual class resistance with NNRTI mutations featuring prominently. The considerable pill burden imposed by the addition of DR-TB treatment to chronic ART is likely to have negatively impacted ART adherence fueling development of ART resistance. These findings are consistent with the published surveillance studies conducted in this setting, reporting the mutations detected in this study as prevalent mutations associated with acquired resistance in adults.[@b15-idr-11-1413],[@b30-idr-11-1413]--[@b34-idr-11-1413] Retrospective analysis of the resistance mutations reveals that patients were receiving inadequate ART for optimal viral suppression. Furthermore, guidelines advocate first-line ART regimen switch without the benefit of ART resistance testing. This coupled with the lack of objective markers of ART adherence comprises early detection and management of ART failure. Most importantly, these cases highlight the need for ongoing clinical monitoring for treatment failure and HIV resistance testing, especially in patients taking complex regimen for multiple concurrent conditions.

Suboptimal adherence to treatment was a key factor driving drug resistance in this subset of patients. Despite receiving enhanced counseling support under clinical trial conditions, patients remained nonadherent. In keeping with previous reports, known behavioral and biologic risk factors such as alcohol misuse, incarceration, hospital admission, poor pill-taking behavior, low level of education attainment, and missed clinic appointments featured among patients failing treatment and acquiring resistance in this study. Despite access to free care for both HIV and TB, underlying social issues severely impacted treatment outcomes underscoring the need for strong ongoing support directed at optimizing treatment adherence and treatment completion.[@b9-idr-11-1413],[@b14-idr-11-1413],[@b16-idr-11-1413],[@b35-idr-11-1413]--[@b39-idr-11-1413] DOTS programs played a pivotal role in increasing treatment completion rates globally. Adopting a similar strategy for the management of DR-TB and HIV coinfection could impact on reducing recurrent TB rates.[@b40-idr-11-1413]--[@b42-idr-11-1413] As reinfection rates are higher in HIV endemic settings like South Africa, we also highlight the need for enhanced infection control measures and ongoing surveillance in congregate settings such as clinic waiting rooms, hospitals, and prisons.[@b43-idr-11-1413],[@b44-idr-11-1413]

We would like to acknowledge study limitations. Secondary study data and stored samples from the study bio-repository were analyzed. We had to rely on self-reported information regarding prior ARV treatment and ART and TB adherence. The lack of availability of objective markers of adherence undermines our ability to understand the evolution of drug resistance to ART and TB drugs. Furthermore, the small sample size limits the generalizability of our findings to other patients and settings. We also did not establish if these patients had mixed strain infection and the extent to which this might have influenced our findings.

In conclusion, the cases described in this series highlight the public health crisis resulting from the intersecting epidemics of DR-TB and drug-resistant HIV. The study underscores the complexity of managing TB and HIV coinfection, and the impact of various risk factors in mediating resistance. Patients failing treatment present a public health risk of ongoing transmission of resistant strains. Distinguishing between relapse and reinfection plays an invaluable role in addressing the burden of recurrent TB disease. High rates of relapse underscore the need for renewed interventions to improve individual patient care while high rates of reinfection underscore the need for improved epidemic control measures. Urgent attention is also required to address challenges of adherence, such as social and health care worker support systems and step-down management facilities. Enhanced treatment options, such as intensified initial treatment, extension of treatment, and preventative therapy for patients presenting with multiple risk factors, will prevent recurrent TB infection. The heightened risk of recurrent TB in ART programs underscores the need for regular TB screening at ART follow-up visits. There has been considerable disparity in the studies reporting on the role of relapse vs reinfection. Further large-scale studies are required to address the role of relapse and reinfection as well as the role of mixed infections in recurrent TB.

Supplementary materials
=======================

Chest radiographs for Patients 1--4 (no images available for Patient 5).

###### 

Chest X-rays of Patient 1 depicting (**A**) infiltrates on both lungs; (**B**) persistent fibrosis in the left lung; and (**C**) cavities in the left lung.

###### 

Chest X-rays of Patient 2 depicting (**A**) infiltrates in both lungs and cavities in the left lung; (**B**) right upper lobe fibrosis; and (**C**) infiltrates in the right lung and infiltrates and new lesions in the left lung.

###### 

Chest X-rays of Patient 3 depicting (**A**) cavities and infiltrates in both lungs; (**B**) cavities and infiltrates on the right lung and fibrosis in the left lung; and (**C**) cavities, infiltrates, and patchy consolidation in the right lung and consolidation in mid and lower zones of the left lung.

###### 

Chest X-rays of Patient 4 depicting (**A**) vast damage to the right lung with cavities, infiltrates, pleural disease, shrinkage, and destruction. Minimal damage to the left lung; (**B**) residual widespread damage to the right lung; and (**C**) right lung bullae and new pleural effusion. New infiltrates in left lung.
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###### 

Epidemiologic and clinical characteristics of five patients with recurrent (M) XDR-TB following drug-susceptible TB

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical and epidemiologic biomarker                                                   Patient 1                                                 Patient 2                                                                    Patient 3                                                                                             Patient 4                                                                                   Patient 5
  -------------------------------------------------------------------------------------- --------------------------------------------------------- ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------
  Age                                                                                    38                                                        32                                                                           38                                                                                                    36                                                                                          30

  Gender                                                                                 M                                                         M                                                                            F                                                                                                     F                                                                                           F

  BMI                                                                                                                                                                                                                                                                                                                                                                                                                             

  BMI at TB-1 diagnosis                                                                  19.4                                                      18.7                                                                         17.6                                                                                                  21.4                                                                                        26

  BMI at TB-1 end                                                                        18.4                                                      20.5                                                                         18.7                                                                                                  23.2                                                                                        26.5

  BMI at TB-2 diagnosis                                                                  21.3                                                      20.4                                                                         17.0                                                                                                  19.4                                                                                        25.8

  Initial episode of TB                                                                                                                                                                                                                                                                                                                                                                                                           

  Date and method of diagnosis                                                           Jul 2007                                                  Jul 2007                                                                     Jan 2007                                                                                              Nov 2007                                                                                    Aug 2005

  X-ray + sputum                                                                         X-ray + sputum                                            X-ray + sputum                                                               X-ray + sputum                                                                                        X-ray + sputum                                                                              

  Genetic and susceptibility profile                                                     Beijing                                                   F15/LAM4/KZN                                                                 F28                                                                                                   F28                                                                                         Unique

  DS-TB                                                                                  DS-TB\                                                    DS-TB                                                                        DS-TB                                                                                                 DS-TB                                                                                       
                                                                                         Lymph aspirate resistant to INH and RIF                                                                                                                                                                                                                                                                                                  

  Chest radiograph                                                                       Infiltrates on RL; cavities and infiltrates on LL         Infiltrates on RL and LL                                                     Cavities, infiltrates, pleural disease, and shrinkage and destruction in RL, minimal fibrosis on LL   Cavities and infiltrates in RL and LL                                                       Cavities and infiltrates in RL and LL

  Completion date, duration on treatment and outcome                                     1 April 2008                                              20 March 2008                                                                20 August 2007                                                                                        Jun 30 2008                                                                                 02 January 06

  8 months                                                                               8 months                                                  10 months                                                                    7 months                                                                                              6 months                                                                                    

  Cure                                                                                   Cure                                                      Cure                                                                         Cure                                                                                                  Cure                                                                                        

  Chest radiograph at the end of treatment                                               Fibrosis in upper RL                                      Fibrosis in LL                                                               Extensive fibrosis                                                                                    Not available                                                                               Not available

  Recurrent MDR/XDR episode of TB                                                                                                                                                                                                                                                                                                                                                                                                 

  Mechanism of recurrence, genetic profile of TB isolates and time to recurrence         Reinfection                                               Relapse                                                                      Reinfection                                                                                           Relapse                                                                                     Relapse

  Beijing to KZN strain                                                                  KZN strain                                                F28 -- unique                                                                F28 strain                                                                                            Unique strain                                                                               

  24 months                                                                              28 months                                                 19 months                                                                    28 months                                                                                             15 months                                                                                   

  Date and method of diagnosis                                                           June 10                                                   Feb 2011                                                                     Apr 2010                                                                                              Nov 2010                                                                                    May 07

  X-ray + sputum culture                                                                 X-ray + sputum                                            X-ray + sputum culture                                                       X-ray + sputum                                                                                        X-ray + sputum                                                                              

  Susceptibility profile                                                                 XDR-TB                                                    MDR-TB                                                                       MDR-TB                                                                                                MDR-TB                                                                                      XDR-TB

  Resistant to INH, RIF, EMB, kanamycin, capreomycin, OFX, Ialiamide, SM, ETH, and PZA   Resistant to INH, RIF, EMB, ETH, PZA, and SM              Resistant to NH, RIF, ETH, SM, and PZA                                       Resistant to INH, EMB, RIF, SM, ETH, and PZA                                                          INH, RIF, EMB, MXF, KANA, and ETH                                                           

  Radiologic findings                                                                    Infiltrates on RL and infiltrates and new lesions on LL   Cavities in LL                                                               Bullae and plural effusion in RL                                                                      Cavities and infiltrates on RL and fibrosis on LL                                           Cavitation in LL

  Treatment outcome                                                                      Transferred out for DR-TB care                            Transferred out for DR-TB care                                               Died                                                                                                  Withdrew from study                                                                         Transferred out for DR-TB care

  HIV history                                                                                                                                                                                                                                                                                                                                                                                                                     

  Date of diagnosis                                                                      Jul 2007                                                  Jul 2007                                                                     Jan 2007                                                                                              Dec 2007                                                                                    2005

  Treatment regimen                                                                      AZT/3TC/EFV, switched AZT to TDF in May 2009              ddI/3TC/EFV (discontinued between March and April 2009)                      ddI/3TC/EFV                                                                                           ddI/3TC/EFV switched to ABC/TDF/LPV/r in October 2008, and back to regimen 1 in June 2011   ddI/3TC/EFV, switched to TDF in July 2011

  Regimen response                                                                       Virologic suppression; sustained high CD4+ cell count     Raised CD4 count and virologic suppression by Month 12                       Good virologic suppression, CD4 cell count remained low                                               Failed both regimens, placed back onto Regimen 1                                            Good virologic suppression, CD4 count remained low

  CD4/VL at initial TB diagnosis                                                         CD4 =200                                                  CD4 =54                                                                      CD4 =151                                                                                              CD4 =245                                                                                    CD4 =205

  VL =260,000                                                                            VL =126,000                                               VL =41,663                                                                   VL = Unavailable                                                                                      VL =83,900                                                                                  

  CD4/VL at the end of first TB episode                                                  CD4 =434                                                  CD4 =377                                                                     CD4 =331                                                                                              CD4 =212                                                                                    CD4 =352

  VL =400                                                                                VL ≤400                                                   VL ≤400                                                                      VL =27,400                                                                                            VL ≤400                                                                                     

  CD4/VL at recurrent TB diagnosis                                                       CD4 =3,652                                                CD4 =565                                                                     CD4 =245                                                                                              CD4 =143                                                                                    CD4 =204

  VL = unavailable                                                                       V ≤400                                                    VL ≤40                                                                       VL =20,302                                                                                            VL =69,400                                                                                  

  Other notes                                                                                                                                                                                                                                                                                                                                                                                                                     

  TB risk profile                                                                        Hospitalization                                           Hospitalization                                                              Hospitalization                                                                                       Household TB contacts                                                                       No risks

  Adherence profile                                                                      Poor; adherence support program                           Fair; missed clinic visits due to alcohol use, occasional missing of doses   Good                                                                                                  Poor; hospitalization for supervised TB treatment                                           Good

  Other medical conditions                                                               Anemia, PN, SN, HepB                                      IRIS on TB treatment, PN                                                     PN, pneumonia in August 2010                                                                          Hypertension, PN                                                                            None

  Substance use history                                                                  Alcohol abuse, smoking                                    Alcohol abuse, smoking                                                       None                                                                                                  None                                                                                        None
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Initial episode of TB = TB-1; Recurrent episode of TB = TB-2 radiological findings from chest x-rays conducted after diagnosis and treatment end (closest date available given).

**Abbreviations:** 3TC, lamivudine; ABC, abacavir; ALV, alluvia; AZT, azidothymidine; BMI, body mass index; CD4, CD4+ T-cell count (cells/µL^3^); DDI, didanosine; EFV, efavirenz; EMB, ethambutol; ETH, ethionamide; Hep B, hepatitis B; INH, isoniazid; LL, left lung; MDR, multi-drug-resistant; OFX, ofloxacin; PN, peripheral neuropathy; PTB, pulmonary TB; PZA, pyrazinamide; R4, Rifafour; RIF, rifampicin; RL, right lung; SM, streptomycin; SN, sensory neuropathy; TB, tuberculosis; TDF, tenofovir; VL, viral load (copies/µL^3^); XDR, extensively drug-resistant.

###### 

HIV drug resistance profiles at TRUTH study entry and exit visits

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
              ART regimen                                                               Drug resistance mutations at TRUTH entry                                              Drug resistance mutations at the end of TRUTH study
  ----------- ------------------------------------------------------------------------- ------------------------------------------------------------------------------------- -----------------------------------------------------
  Patient 1   AZT/3TC/EFV switched to TDF/3TC/EFV                                       NRTI: D67N; K70R; M184V; *T215I*[a](#tfn3-idr-11-1413){ref-type="table-fn"}; K219E\   NRTI: M184V\
                                                                                        NNRTI: V106M; *Y188F*[b](#tfn4-idr-11-1413){ref-type="table-fn"}; M230L               NNRTI: K103N; G190A; Y188L

  Patient 2   ddI/3TC/EFV                                                               None                                                                                  NRTI: M184V\
                                                                                                                                                                              NNRTI: V106M; Y188L

  Patient 3   ddI/3TC/EFV                                                               NRTI: T215S[b](#tfn4-idr-11-1413){ref-type="table-fn"}\                               NRTI: K70E; M184V\
                                                                                        NNRTI: K103N                                                                          NNRTI: K103N

  Patient 4   ddI/3TC/EFV switched to ABC/TDF/LPV/r then switched back to ddI/3TC/EFV   None                                                                                  NRTI: M184V\
                                                                                                                                                                              NNRTI: K101E; K103N; G190A

  Patient 5   ddI/3TC/EFV switched to TDF/3TC/EFV                                       None                                                                                  NRTI: M184I\
                                                                                                                                                                              NNRTI: V106M; Y188C; H221Y
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Revertant mutation;

Transitional mutation. None of the patients had any resistance associated mutation prior to the initiation of treatment.

**Abbreviations:** 3TC, lamivudine; ABC, abacavir; ddI, didanosine; AZT, zidovudine; EFV, efavirenz; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; LPV/r, lopinavir-boosted ritonavir (Aluvia; Abbott, South Africa).
